Business
CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia
VIENNA, Va., May 21, 2025--CEL-SCI’S Multikine investigational cancer medicine potentially available for commercialization by summer 2025 in Saudi Arabia.
About this update from Cel-sci Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":240,"url":"https://media.zenfs.com/en/business-wire.com/50cd68f82159e85ca80773e7afd12b8c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9_iwjiX7ZTm.sQlTr_CzLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/50cd68f82159e85ca80773e7afd12b8c","width":480,"height":240}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Saudi Arabia’s new Breakthrough Medicine Designation, if granted, would make Multikine available for patient access and commercial use","length":134,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Saudi Food and Drug Authority typically responds to Breakthrough Medicine Designation applications within approximately 60 days","length":127,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Multikine increased the 5-year survival rate of the target patient population in head and neck cancer to 73% vs 45% in patients treated with standard of care alone; The 5-year risk of death was halved from 55% to 27%","length":216,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":477,"olType":false},{"type":"text","content":"VIENNA, Va., May 21, 2025--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced it has completed its Breakthrough Medicine Designation application for Multikine* (Leukocyte Interleukin, Injection) for submission to the Saudi Food and Drug Authority (SFDA) in Saudi Arabia. Multikine is an immunotherapy administered before surgery as a treatment for newly diagnosed previously untreated head and neck cancer.","length":429,"tagName":"p"},{"type":"text","content":"The Breakthrough Designation Application is expected to be formally submitted to the SFDA on CEL-SCI’s behalf within the next few weeks by the Company’s prospective Saudi partner, one of the country’s premier pharmaceutical and healthcare companies. According to the SFDA, the response time to a Breakthrough Medicine Designation application is approximately 60 days.","length":367,"tagName":"p"},{"type":"text","content":""We are very excited that Multikine could become available to patients in Saudi Arabia as early as this summer," stated CEL-SCI CEO Geert Kerst...